Type 1 Diabetes

The updated branding better reflects the group's mission of research and advocacy.

In the course of investigating the use of Bacillus Calmette-Guérin for high-risk individuals who have type 1 diabetes (T1D), researchers hoped—and found—that BCG could substantially reduce the chance of those with T1D contracting COVID-19; BCG has historically been used to prevent tuberculosis (TB).

A new report builds on previous research that could help scientists better understand type 1 diabetes (T1D) risk.

A retrospective study of over 100 pediatric and adolescent patients showed that providing virtual training for insulin pump use was both safe and effective.

HHS officials are moving forward with a plan to produce 4.8 million doses of H5N1 avian flu vaccine; Novo Nordisk’s long-acting insulin had a greater risk of excessively lowering patients’ blood sugar without offering better sugar level management; Los Angeles County launched an ambitious effort to tackle medical debt.

Although an aerobic cooldown indeed lowers blood glucose levels in adults with type 1 diabetes after fasted exercise, by itself, the impact it has on hyperglycemia is insignificant.

The results of T1International’s 2022 Out-of-Pocket Expenses survey highlight many huge inequities in the US and around the world relating to insulin and diabetes care supplies.

Patients with type 1 diabetes (T1D) reported improved glucose outcomes, but they also said their sleep and quality of life benefited.

Findings from the FAMS-T1D study demonstrate that structured goal-setting and achievement significantly enhance self-efficacy and self-care in emerging adults who have type 1 diabetes (T1D).

Type 1 diabetes (T1D), which once predominantly affected children, is increasingly affecting older adults in the US, with prevalence rates peaking in those aged 45 to 64, according to recent research.

JAMA used a case report of rhino-orbital-cerebral mucormycosis in a patient with uncontrolled diabetes to demonstrate correct and incorrect treatment choices.

The connection was primarily established between type 1 diabetes (T1D) and the eating disorders bulimia and binge eating, with female patients with T1D at higher risk of insulin misuse as a result.

The LIFE-T1D model, demonstrated an ability to estimate the lifetime risk of heart disease among several groups of people with type 1 diabetes (T1D).

Previous research links type 2 diabetes and metabolic dysfunction–associated steatotic liver disease (MASLD).

Similar burdens were observed among both children with a diagnosis of type 1 diabetes (T1D) and their informal caregivers, both at the time of diagnosis and when the disease was already established.

Individual variations in cognitive performance based on fluctuating glucose levels were observed, necessitating further research on the topic.

This finding on continuous glucose monitoring (CGM) remained even after the researchers adjusted for glycemic control according to HbA1C levels.

This secondary analysis follows initial results from a phase 3 trial, which suggested that vitamin D supplementation with ergocalciferol improved insulin sensitivity, subsequently slowing the rise of insulin requirements in patients who have type 1 diabetes (T1D).

Increased interest in screening for the genetic risk of type 1 diabetes (T1D) has been driven by factors including the introduction of immune interventions.

However, prevalence was found to plateau over time, suggesting neuropathic pain may be isolated or intermittent events in some patients with type 1 diabetes.

The pump had varying success in reaching recommended glycemic targets among the study participants with type 1 diabetes (T1D).

Outside of genetics, which has a well-documented link to the risk of type 1 diabetes (T1D), investigators detail available research spanning a variety of factors, including viral infections, pesticide exposure, and the gut microbiome.

Using home insulin pumps when hospitalized was relatively safe compared with hospital-managed pumps and insulin injections among more than 2700 children admitted to a single hospital center.

These findings suggest complement protein levels may be an important biomarker for type 1 diabetes.

The findings follow endorsement of the screening measure from the American Diabetes Association, which recommended the practice to identify patients who have type 1 diabetes (T1D) who could benefit from targeted strategies to prevent symptomatic heart failure (HF).

Investigators say adolescents had difficulty adhering to the workbook-based program, but the authors said changes—and perhaps a digital format—could improve the program’s performance.

Having multiple readmissions for diabetes ketoacidosis (DKA) was more likely to occur among patients with type 1 diabetes (T1D) with substance use disorder or who previously were incarcerated.

A new study challenges assumptions about the role of dietary protein and fat in managing blood glucose fluctuations, known as glycemic variability.

A real-world study conducted across 9 European countries found that bolus injection frequency and engagement with a smart pen to administer insulin were associated with improved glycemic control among young adult patients with type 1 diabetes (T1D).

In a systematic review and meta-analysis, real-time continuous glucose monitoring (CGM) demonstrated benefits in terms of time in range, hypoglycemia, and hyperglycemia among patients with type 1 diabetes (T1D).